Company Filing History:
Years Active: 1998
Title: B Catimel: Innovator in Cancer Research
Introduction
B Catimel is a notable inventor based in Victoria, Australia. He has made significant contributions to the field of cancer research, particularly through his innovative work on isolated proteins and peptides that have implications for cancer diagnostics and therapeutics.
Latest Patents
B Catimel holds a patent for an isolated protein that binds to the A33 antibody, along with corresponding peptides. This invention pertains to proteins and peptides found on the surface of colon cells and colon cancer cells. The protein and peptides are designed to bind to tumor-associated antibodies, such as mAb A33. The monomeric protein has a molecular weight of about 43 kD, as determined by SDS gel electrophoresis under non-reducing conditions. Furthermore, this invention encompasses the use of nucleic acid molecules, proteins in both monomeric and multimeric forms, and antibodies to these peptides in various diagnostic, screening, and therapeutic methods.
Career Highlights
B Catimel is affiliated with the Ludwig Institute for Cancer Research Limited, where he continues to advance his research in cancer biology. His work has been instrumental in understanding the interactions between proteins and cancer cells, paving the way for potential new treatments.
Collaborations
Throughout his career, B Catimel has collaborated with esteemed colleagues, including Lloyd J Old and Sydney Welt. These partnerships have enhanced the scope and impact of his research in the field of cancer.
Conclusion
B Catimel's innovative contributions to cancer research, particularly through his patented work on isolated proteins and peptides, highlight his role as a significant figure in the scientific community. His ongoing research continues to hold promise for advancements in cancer diagnostics and therapies.